Pre-surgery targeted drugs for selected colorectal cancer tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests targeted cancer drugs given before planned colon or rectal surgery. It may help by trying to shrink the tumor and treat specific tumor “targets” found in your stored pathology sample, depending on your tumor’s genetics and marker tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent and you’re at least 18 years old.
- Your colon/rectal cancer is confirmed as adenocarcinoma and is judged operable with surgery aiming to fully remove it (R0 margins).
- Your scans show no distant spread (no metastases on CT chest/abdomen/pelvis).
- You have no need for pre-surgery radiation/chemoradiation for rectal cancer (based on the study team).
- Your tumor sample already available from diagnosis (FFPE tissue) is enough for genetic/molecular testing, and you match one of the study’s molecular groups.
- You have good blood counts and organ function (bone marrow, kidney, and liver), and your heart pumping strength is high enough where required; you also must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan and cetuximab, for people with colorectal cancer that has spread or cannot be removed. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests whether adding two newer drugs to standard chemotherapy before surgery can shrink rectal tumors more effectively. It is for patients whose tumors are not too low in the rectum and have certain genetic markers.
This trial tests treatments given before surgery for colorectal cancer that has not spread. The goal is to shrink the tumor and improve surgical outcomes. It may be an option for patients with stage II or III colorectal cancer who have not had prior treatment.
This trial tests whether giving chemotherapy before surgery can improve outcomes for patients with colon cancer that has not spread to other parts of the body. The treatment aims to shrink the tumor and reduce the chance of the cancer coming back.
This trial tests a combination of two targeted drugs, with or without chemotherapy, given before and after surgery for stomach or gastroesophageal junction cancer. It aims to improve the chance of curing the cancer by shrinking it before surgery and controlling any remaining cancer after surgery.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.